SEARCH

SEARCH BY CITATION

References

  • Adachi T, Harumiya S, Takematsu H, Kozutsumi Y, Wabl M, Fujimoto M, Tedder TF (2011) CD22 serves as a receptor for soluble IgM. Eur J Immunol 42: 241- 247
  • Ammann JU, Jahnke M, Dyson MR, Kaufman J, Trowsdale J (2012) Detection of weak receptor-ligand interactions using IgM and J-chain-based fusion proteins. Eur J Immunol 42: 1354- 1356
  • Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110- 113
  • Arnason JE, Campigotto F, Neuberg D, Bussel JB (2012) Abnormalities in IgA and IgM are associated with treatment-resistant ITP. Blood 119: 5016- 5020
  • Bajtay Z, Csomor E, Sandor N, Erdei A (2006) Expression and role of Fc- and complement-receptors on human dendritic cells. Immunol Lett 104: 46- 52
  • Bakema JE, van Egmond M (2011a) The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 4: 612- 624
  • Bakema JE, van Egmond M (2011b) Immunoglobulin A: a next generation of therapeutic antibodies? MAbs 3: 352- 361
  • Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, Lohse S, Glennie MJ, Medema JP, van Egmond M (2011) Targeting FcalphaRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol 187: 726- 732
  • Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, Sandlie I, Chen Z, de Haar C, Lencer WI, et al (2011) Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci USA 108: 9927- 9932
  • Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, van Egmond M, Challacombe S, Woof JM, Ivanyi J (2011) A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 186: 3113- 3119
  • Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3: 415- 416
  • Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D, Nimmerjahn F (2011) Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932- 944
  • Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, et al (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 101: 9763- 9768
  • Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716- 3725
  • Canal F, Sanchis J, Vicent MJ (2011) Polymer–drug conjugates as nano-sized medicines. Curr Opin Biotechnol 22: 894- 900
  • Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, et al (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525- 531
  • Carrillo-Conde B, Song EH, Chavez-Santoscoy A, Phanse Y, Ramer-Tait AE, Pohl NL, Wannemuehler MJ, Bellaire BH, Narasimhan B (2011) Mannose-functionalized “pathogen-like” polyanhydride nanoparticles target C-type lectin receptors on dendritic cells. Mol Pharm 8: 1877- 1886
  • Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317: 1261- 1269
  • Cervenak J, Bender B, Schneider Z, Magna M, Carstea BV, Liliom K, Erdei A, Bosze Z, Kacskovics I (2011) Neonatal FcR overexpression boosts humoral immune response in transgenic mice. J Immunol 186: 959- 968
  • Congy-Jolivet N, Probst A, Watier H, Thibault G (2007) Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol/Hematol 64: 226- 233
  • Cox GN, Smith DJ, Carlson SJ, Bendele AM, Chlipala EA, Doherty DH (2004) Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp Hematol 32: 441- 449
  • Czajkowsky DM, Salanti A, Ditlev SB, Shao Z, Ghumra A, Rowe JA, Pleass RJ (2010) IgM, Fc mu Rs, and malarial immune evasion. J Immunol 184: 4597- 4603
  • Daeron M, Malbec O, Latour S, Arock M, Fridman WH (1995) Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 95: 577- 585
  • Dall'Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281: 23514- 23524
  • Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS (2010) SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 23: 195- 202
  • Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL (2007) Soluble Fc fusion proteins for biomedical research. Methods Mol Biol 378: 33- 52
  • Gaboriaud C, Juanhuix J, Gruez A, Lacroix M, Darnault C, Pignol D, Verger D, Fontecilla-Camps JC, Arlaud GJ (2003) The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 278: 46974- 46982
  • Getahun A, Heyman B (2006) How antibodies act as natural adjuvants. Immunol Lett 104: 38- 45
  • Getahun A, Dahlstrom J, Wernersson S, Heyman B (2004) IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors. J Immunol 172: 5269- 5276
  • Gil M, Bieniasz M, Wierzbicki A, Bambach BJ, Rokita H, Kozbor D (2009) Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J Immunol 183: 6808- 6818
  • Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, Eaton DL (2005) A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 102: 1116- 1121
  • Griffiss JM, Goroff DK (1983) IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol 130: 2882- 2885
  • Harte PG, Cooke A, Playfair JH (1983) Specific monoclonal IgM is a potent adjuvant in murine malaria vaccination. Nature 302: 256- 258
  • Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275- 1286
  • Heldwein EE, Krummenacher C (2008) Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 65: 1653- 1668
  • Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58: 2443- 2452
  • Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T (2010) Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49: 1215- 1228
  • Hsu TL, Cheng SC, Yang WB, Chin SW, Chen BH, Huang MT, Hsieh SL, Wong CH (2009) Profiling carbohydrate-receptor interaction with recombinant innate immunity receptor-Fc fusion proteins. J Biol Chem 284: 34479- 34489
  • Huang C (2009) Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 20: 692- 699
  • Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG (2001) Engineered antibodies with increased activity to recruit complement. J Immunol 166: 2571- 2575
  • Jefferis R (2007) Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7: 1401- 1413
  • Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8: 226- 234
  • Jensen MA, Arnason BG, White DM (2007) A novel Fc gamma receptor ligand augments humoral responses by targeting antigen to Fc gamma receptors. Eur J Immunol 37: 1139- 1148
  • Jung K, Lee JE, Kim HZ, Kim HM, Park BS, Hwang SI, Lee JO, Kim SC, Koh GY (2009) Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis. PloS one 4: e7403
  • Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, Dodev T, Koers A, Blower PJ, Corrigan C, et al (2011) Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother DOI: 10.1007/s00262-011-1162-8
  • Kardava L, Moir S, Wang W, Ho J, Buckner CM, Posada JG, O'Shea MA, Roby G, Chen J, Sohn HW, et al (2011) Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest 121: 2614- 2624
  • Kaveri SV, Silverman GJ, Bayry J (2012) Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol 188: 939- 945
  • Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22: 868- 876
  • Kumar M, Hunag Y, Glinka Y, Prud'homme GJ, Wang Q (2007) Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther 14: 162- 172
  • Leroux-Roels G (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 Suppl 3, C25- C36
  • Li F, Ravetch JV (2011) Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333: 1030- 1034
  • Lin JC, Ho WH, Gurney A, Rosenthal A (2003) The netrin-G1 ligand NGL-1 promotes the outgrowth of thalamocortical axons. Nat Neurosci 6: 1270- 1276
  • Lofblom J, Frejd FY, Stahl S (2011) Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol 22: 843- 848
  • Logan GJ, Wang L, Zheng M, Ginn SL, Coppel RL, Alexander IE (2009) Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules. Gene Ther 16: 200- 210
  • Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T (2011) Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 186: 3770- 3778
  • Lu L, Palaniyandi S, Zeng R, Bai Y, Liu X, Wang Y, Pauza CD, Roopenian DC, Zhu X (2011) A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol 85: 10542- 10553
  • Mammen M, Choi SK, Whitesides GM (1998) Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Edit 37: 2755- 2794
  • Martin WL, Bjorkman PJ (1999) Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 38: 12639- 12647
  • Mathew GD, Qualtiere LF, Neel HB, III, Pearson GR (1981) IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer J Int Cancer 27: 175- 180
  • McEwan WA, Mallery DL, Rhodes DA, Trowsdale J, James LC (2011) Intracellular antibody-mediated immunity and the role of TRIM21. BioEssays 33: 803- 809
  • Mekhaiel DN, Daniel-Ribeiro CT, Cooper PJ, Pleass RJ (2011a) Do regulatory antibodies offer an alternative mechanism to explain the hygiene hypothesis? Trends Parasitol 27: 523- 529
  • Mekhaiel DN, Czajkowsky DM, Andersen JT, Shi J, El-Faham M, Doenhoff M, McIntosh RS, Sandlie I, He J, Hu J, et al (2011b) Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep 1: 124
  • Morell A, Terry WD, Waldmann TA (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49: 673- 680
  • Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer D, et al (2011) Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 24: 447- 454
  • Nagashima H, Kaneko K, Yamanoi A, Motoi S, Konakahara S, Kohroki J, Masuho Y (2011) TNF receptor II fusion protein with tandemly repeated Fc domains. J Biochem 149: 337- 346
  • Nelson AL (2010) Antibody fragments: hope and hype. MAbs 2: 77- 83
  • Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody fragments. Nat Biotechnol 27: 331- 337
  • Nigro EA, Soprana E, Brini AT, Ambrosi A, Yenagi VA, Dombrowicz D, Siccardi AG, Vangelista L (2012) An antitumor cellular vaccine based on a mini-membrane IgE. J Immunol 188: 103- 110
  • Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34- 47
  • O'Reilly MK, Collins BE, Han S, Liao L, Rillahan C, Kitov PI, Bundle DR, Paulson JC (2008) Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells. J Am Chem Soc 130: 7736- 7745
  • Peipp M, Dechant M, Valerius T (2008) Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 20: 436- 443
  • Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174: 1483- 1489
  • Pfirsch-Maisonnas S, Aloulou M, Xu T, Claver J, Kanamaru Y, Tiwari M, Launay P, Monteiro RC, Blank U (2011) Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized “inhibisome” clusters. Sci Signal 4: ra24
  • Quan CP, Watanabe S, Forestier F, Bouvet JP (1998) Human amniotic IgA inhibits natural IgG autoantibodies of maternal or unrelated origin. Eur J Immunol 28: 4001- 4009
  • Ramani SR, Tom I, Lewin-Koh N, Wranik B, Depalatis L, Zhang J, Eaton D, Gonzalez LC (2012) A secreted protein microarray platform for extracellular protein interaction discovery. Anal Biochem 420: 127- 138
  • Rapaka RR, Ricks DM, Alcorn JF, Chen K, Khader SA, Zheng M, Plevy S, Bengten E, Kolls JK (2010) Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med 207: 2907- 2919
  • Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG (2001) IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res 61: 5517- 5522
  • Redpath S, Michaelsen TE, Sandlie I, Clark MR (1998) The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Hum Immunol 59: 720- 727
  • Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, et al (1999) Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189: 371- 380
  • Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3: 76- 99
  • Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715- 725
  • Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (2009) Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 113: 6161- 6171
  • Saad JS, Miller J, Tai J, Kim A, Ghanam RH, Summers MF (2006) Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci USA 103: 11364- 11369
  • Salfeld JG (2007) Isotype selection in antibody engineering. Nat Biotechnol 25: 1369- 1372
  • Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088- 1094
  • Santiago T, Kulemzin SV, Reshetnikova ES, Chikaev NA, Volkova OY, Mechetina LV, Zhao M, Davis RS, Taranin AV, Najakshin AM, et al (2011) FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA. Int Immunol 23: 43- 53
  • Saxon A, Kepley C, Zhang K (2008) “ Accentuate the negative, eliminate the positive”: engineering allergy therapeutics to block allergic reactivity through negative signaling. J Allergy Clin Immunol 121: 320- 325
  • Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418- 426
  • Schwab I, Biburger M, Kronke G, Schett G, Nimmerjahn F (2012) IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 42: 826- 830
  • Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S (2010) IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116: 1698- 1704
  • Shi J, McIntosh RS, Adame-Gallegos J, Dehal PK, van Egmond M, van de Winkel J, Draper SJ, Forbes EK, Corran PH, Holder AA, et al (2011) The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19). BMC Biotechnol 11: 77
  • Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al (2003) The absence of fucose but not the presence of galactose or bisecting N-N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278: 3466- 3473
  • Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa R, Nakamura K, Shitara K (2006) Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem 140: 777- 783
  • Sidhu SS, Fellouse FA (2006) Synthetic therapeutic antibodies. Nat Chem Biol 2: 682- 688
  • Smith P, Dilillo DJ, Bournazos S, Li F, Ravetch JV (2012) Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci USA 109: 6181- 6186
  • Soltani N, Kumar M, Glinka Y, Prud'homme GJ, Wang Q (2007) In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 14: 981- 988
  • Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F, Kaye PM (2003) Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 9: 1287- 1292
  • Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al (2011) Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2: 599
  • Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E (2008) Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv Enzyme Regul 48: 152- 164
  • Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20: 685- 691
  • Strohl WR, Knight DM (2009) Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol 20: 668- 672
  • Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184: 1968- 1976
  • Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 24: 263- 271
  • Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774- 1785
  • Van Scott MR, Mertsching E, Negrou E, Miles J, Stallings HW, III, Graff C, Kehry MR (2008) Systemic administration of an Fcgamma-Fc(epsilon)-fusion protein in house dust mite sensitive nonhuman primates. Clin Immunol 128: 340- 348
  • Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118: 3347- 3349
  • Vire B, David A, Wiestner A (2011) TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. J Immunol 187: 4040- 4050
  • Vollmers HP, Brandlein S (2006) Natural IgM antibodies: the orphaned molecules in immune surveillance. Adv Drug Deliv Rev 58: 755- 765
  • Wang Q, Chen K, Liu R, Zhao F, Gupta S, Zhang N, Prud'homme GJ (2010) Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PloS one 5: e12734
  • Weiner GJ (2010) Rituximab: mechanism of action. Sem Hematol 47: 115- 123
  • West AP, Jr., Galimidi RP, Gnanapragasam PN, Bjorkman PJ (2012) Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol 86: 195- 202
  • Wilson TJ, Gilfillan S, Colonna M, (2010) Fc receptor-like A associates with intracellular IgG and IgM but is dispensable for antigen-specific immune responses. J Immunol 185: 2960- 2967
  • Wilson TJ, Fuchs A, Colonna M (2012) Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol 188: 4741- 4745
  • Wines BD, Trist HM, Farrugia W, Ngo C, Trowsdale J, Areschoug T, Lindahl G, Fraser JD, Ramsland PA (2012) A conserved host and pathogen recognition site on immunoglobulins: structural and functional aspects. Adv Exp Med Biol 946: 87- 112
  • Wojtowicz WM, Wu W, Andre I, Qian B, Baker D, Zipursky SL (2007) A vast repertoire of Dscam binding specificities arises from modular interactions of variable Ig domains. Cell 130: 1134- 1145
  • Woof JM, Burton DR (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4: 89- 99
  • Wright GJ (2009) Signal initiation in biological systems: the properties and detection of transient extracellular protein interactions. Mol Biosyst 5: 1405- 1412
  • Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X (2011) Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 29: 158- 163
  • Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182: 7663- 7671
  • Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28: 157- 159
  • Zhang J, Carter J, Siu S, O'Neill JW, Gates AH, Delaney J, Mehlin C (2010) Fusion partners as a tool for the expression of difficult proteins in mammalian cells. Curr Pharm Biotechnol 11: 241- 245
  • Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, et al (2001) MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 166: 3266- 3276